Related references
Note: Only part of the references are listed.Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naive patients with neovascular age-related macular degeneration
Salomon-Yves Cohen et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2023)
Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study
Lihteh Wu et al.
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS (2022)
Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis
Mathew W. MacCumber et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2021)
Real-World Treatment Patterns in a Population With Neovascular AMD Treated With Anti-VEGF Agents
Catherine A. Urbano et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2021)
Visual Acuity Outcomes in Patients Receiving Frequent Treatment of Neovascular Age-Related Macular Degeneration in Clinical Practice
Andrew A. Moshfeghi et al.
JOURNAL OF VITREORETINAL DISEASES (2021)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Age-Related Macular Degeneration Preferred Practice Pattern®
Timothy W. Olsen et al.
OPHTHALMOLOGY (2020)
Management and Outcomes for Neovascular Age-Related Macular Degeneration Analysis of United States Electronic Health Records
Szilard Kiss et al.
OPHTHALMOLOGY (2020)
Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients A Real-World Analysis of 49 485 Eyes
Thomas A. Ciulla et al.
OPHTHALMOLOGY RETINA (2020)
Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases
Peter K. Kaiser et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
Saira Khanna et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Adam R. Glassman et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration-Primary End Point
David M. Brown et al.
OPHTHALMOLOGY (2013)
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Brandon G. Busbee et al.
OPHTHALMOLOGY (2013)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2011)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
